EAM Investors’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History

EAM Investors’s Portfolio MNTA Stock Details MNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-61,218	Closed	-$2.04M	–	392
2020 Q2	$2.04M	Buy	61,218 +962	+2%	+$30.6K	0.45%	81
2020 Q1	$1.64M	Buy	+60,256	New	+$1.68M	0.51%	86
2015 Q3	–	Sell	-164,534	Closed	-$3.75M	–	372
2015 Q2	$3.75M	Buy	+164,534	New	+$3.28M	0.44%	73

Other funds holding MNTA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return

EAM Investors's MNTA Position: Q3 2020 in Review

EAM Investors sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q3 2020, closing a stake of 61,218 shares — an estimated $2.04M sold.

EAM Investors first reported a position in MNTA in Q2 2015 and held it in 3 quarters. The position peaked at $3.75M in Q2 2015. 211 funds tracked by Wall St. Rank hold MNTA as of Q3 2020.

EAM Investors reported no remaining Momenta Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
EAM Investors sold 61,218 Momenta Pharmaceuticals, Inc. shares in Q3 2020, an estimated $2.04M.
EAM Investors first reported a position in Momenta Pharmaceuticals, Inc. in Q2 2015 and held it in 3 quarters.
EAM Investors's Momenta Pharmaceuticals, Inc. position peaked at $3.75M in Q2 2015.
211 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q3 2020.

Based on EAM Investors's 13F filing for Q3 2020, filed 13 Nov 2020.